Hepatic and Renal Clearance: Protein Binding, the Well-Stirred Model, and Renal Elimination Mechanisms

Lecture Notes

1 1. Recap: High vs. Low Extraction Ratio Drugs

Last session covered the classification of drugs into high and low extraction ratio categories, and the processes that drive that classification. This session dives deeper into two of those processes: the impact of plasma protein binding, and permeability with transporter location. It concludes with renal clearance mechanisms.

2 2. Impact of Plasma Protein Binding on Hepatic Clearance

2.1 2.1 High Extraction Ratio Drugs

For a high extraction ratio drug, the dominant process governing elimination is the intrinsic enzymatic capacity of the liver — the liver metabolizes essentially all drug that reaches it. The extraction ratio is defined as:

\[E_H = 1 - \frac{C_{B,\text{out}}}{C_{B,\text{in}}}\]

When protein binding changes — whether the fraction unbound increases or decreases — both $C_{B,\text{in}}$ and $C_{B,\text{out}}$ change proportionally. For example, if the ratio was originally $4/4$, it becomes $2/2$ after increased binding; the extraction ratio remains unchanged.

Because elimination by the liver is so dominant in high extraction ratio drugs, whatever drug is unbound and enters the hepatocyte is immediately metabolized — assuming no permeability barrier. Therefore:

For high extraction ratio drugs, changes in plasma protein binding have negligible impact on hepatic clearance.

This is a clinically critical concept. For instance, if a patient is on rifampin (a highly protein-bound drug) and laboratory results indicate a change in albumin levels, the dose need not be adjusted if rifampin is a high extraction ratio drug.

2.2 2.2 Low Extraction Ratio Drugs

For a low extraction ratio drug, the unbound arterial concentration equals the unbound venous concentration:

\[C_{A,u} = C_{V,u}\]

At equilibrium — assuming no barriers to penetration — the unbound concentration in the sinusoid equals the unbound intracellular concentration in the hepatocyte:

\[C_u = C_{u,H}\]

The rate of elimination can then be written as:

\[\text{Rate of elimination} = CL_{\text{int}} \cdot C_{u,H} = CL_{\text{int}} \cdot C_u = CL_{\text{int}} \cdot f_u \cdot C\]

Since hepatic clearance is defined as the rate of elimination divided by concentration:

\[CL_H = \frac{\text{Rate of elimination}}{C} = CL_{\text{int}} \cdot f_u\]

Therefore, for a low extraction ratio drug:

Hepatic clearance is directly proportional to the fraction unbound ($f_u$) and intrinsic clearance ($CL_{\text{int}}$). If $f_u$ increases, $CL_H$ increases proportionally.

This is a fundamental concept. The reason the drug is classified as low extraction is precisely because the enzyme’s inherent capacity to metabolize it is low; therefore, the hepatic clearance becomes dependent on plasma protein binding.

3 3. The Well-Stirred Model

3.1 3.1 Fundamental Assumptions

The Well-Stirred model (also called the Rowland-Benet model) rests on two core assumptions:

The unbound drug concentration is rapidly equilibrating and uniformly distributed across the entire organ — including the sinusoids, interstitial spaces, and intracellular hepatocytes.
The system is at steady state.

3.2 3.2 Derivation

Starting from a mass balance on the liver:

\[V_H \frac{dC_H}{dt} = Q_H \cdot C_{B,\text{in}} - Q_H \cdot C_{B,\text{out}} - CL_{\text{int}} \cdot C_{u,\text{cell}}\]

The unbound intracellular concentration is:

\[C_{u,\text{cell}} = f_{u,B} \cdot C_{B,\text{out}}\]

Substituting and applying the steady-state condition ($dC_H/dt = 0$):

\[Q_H \cdot C_{B,\text{in}} = C_{B,\text{out}} \left(Q_H + f_{u,B} \cdot CL_{\text{int}}\right)\]

Rearranging:

\[\frac{C_{B,\text{out}}}{C_{B,\text{in}}} = \frac{Q_H}{Q_H + f_{u,B} \cdot CL_{\text{int}}}\]

Since $E_H = 1 - C_{B,\text{out}}/C_{B,\text{in}}$:

\[\boxed{E_H = \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H + f_{u,B} \cdot CL_{\text{int}}}}\]

This is the central equation of the Well-Stirred model. It unifies three determinants of extraction ratio: fraction unbound, intrinsic clearance, and hepatic blood flow.

3.3 3.3 Limiting Cases

High Extraction Ratio ($E_H \to 1$):

When $f_{u,B} \cdot CL_{\text{int}} \gg Q_H$, the $Q_H$ term in the denominator is negligible:

\[E_H \approx \frac{f_{u,B} \cdot CL_{\text{int}}}{f_{u,B} \cdot CL_{\text{int}}} = 1\]

Since $CL_H = Q_H \cdot E_H$:

\[CL_H \approx Q_H\]

Hepatic clearance for high extraction ratio drugs is flow-limited — it depends only on blood flow.

Low Extraction Ratio ($E_H \ll 1$, typically $< 0.3$):

When $Q_H \gg f_{u,B} \cdot CL_{\text{int}}$:

\[E_H \approx \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H}\]

Then:

\[CL_H = Q_H \cdot E_H \approx Q_H \cdot \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H} = f_{u,B} \cdot CL_{\text{int}}\]

Hepatic clearance for low extraction ratio drugs depends only on $f_{u,B}$ and $CL_{\text{int}}$ — not on blood flow.

Note the important distinction: the extraction ratio itself still depends on all three parameters ($f_{u,B}$, $CL_{\text{int}}$, $Q_H$), but the clearance collapses to only two of them for low extraction drugs.

3.4 3.4 Extension: Permeability-Surface Area Model

At the cellular level, permeability of the hepatocyte membrane is also relevant. Incorporating the permeability-surface area product ($PS_{\text{in}}$), the clearance can be expressed as:

\[CL_H = \frac{Q_H \cdot f_{u,B} \cdot PS_{\text{in}}}{Q_H + f_{u,B} \cdot PS_{\text{in}}}\]

The same limiting-case logic applies. For most practical purposes, the simpler $f_{u,B} \cdot CL_{\text{int}}$ formulation is sufficient.

4 4. Permeability and Transporter Location

The Well-Stirred model assumes that permeability is not rate-limiting. In practice, if a drug has low lipophilicity or a large molecular weight, passive permeability into the hepatocyte may be insufficient. Active transporters at the sinusoidal membrane can compensate, but these cases must be evaluated experimentally on a molecule-by-molecule basis and cannot be resolved through equations alone.

5 5. Enterohepatic Recycling

In addition to metabolism, elimination from the hepatocyte can occur via biliary excretion (secretion into bile). This pathway is generally relevant only for small molecular weight drugs. The sequence is:

Drug in hepatocyte is secreted into bile.
Bile is stored in the gallbladder.
Upon gallbladder emptying, bile enters the small intestine via the bile duct.
Drug in the small intestine may be reabsorbed into systemic circulation.

This cycle is called enterohepatic recycling. A pharmacokinetic consequence is the appearance of a double-peak phenomenon in plasma concentration-time profiles: a primary absorption peak followed by a secondary peak coinciding with gallbladder emptying and reabsorption from the gut.

6 6. Renal Clearance

6.1 6.1 Overview of Mechanisms

Drugs appear in urine due to three processes in the nephron:

Filtration — passive movement of unbound drug from blood into the glomerular filtrate (proximal tubule).
Secretion — active transport of drug from blood into the tubular lumen (proximal tubule).
Reabsorption — passive or active movement of drug from the tubular lumen back into blood (proximal and distal tubules).

The net rate of renal excretion is:

\[\text{Rate of excretion} = (1 - F_R)\left(\text{Rate of filtration} + \text{Rate of secretion}\right)\]

where $F_R$ is the fraction reabsorbed. Dividing by plasma concentration gives:

\[CL_R = CL_F + CL_S\]

where $CL_F$ is filtration clearance and $CL_S$ is secretion clearance.

6.2 6.2 Glomerular Filtration

Approximately 20–25% of cardiac output (roughly 1.1 L/min) perfuses the kidneys. Of this, approximately 10% is filtered at the glomerulus:

\[\text{GFR} \approx 0.10 \times 1{,}100 \text{ mL/min} = 120 \text{ mL/min (in a 70 kg individual)}\]

This value is the glomerular filtration rate (GFR), a key clinical parameter for assessing renally eliminated drugs.

Only unbound drug is filtered. The rate of filtration is:

\[\text{Rate of filtration} = GFR \cdot C_u = GFR \cdot f_u \cdot C\]

If filtration is the sole elimination pathway, then the rate of urinary excretion equals the rate of filtration, and:

\[CL_R = \frac{\text{Rate of excretion}}{C} = f_u \cdot GFR\]

The extraction ratio for such a drug is inherently low. Since GFR ≈ 120 mL/min and renal blood flow ≈ 1,100 mL/min, the extraction ratio is approximately 0.11 — low regardless of the drug’s characteristics.

6.3 6.3 Tubular Secretion

Secretion is an active process occurring in the proximal tubule. It is inferred when the observed renal clearance exceeds the filtration clearance:

\[CL_R > f_u \cdot GFR \implies \text{secretion is present}\]

Example: If $f_u = 0.5$ and $GFR = 120$ mL/min, the filtration clearance is 60 mL/min. If the measured $CL_R = 80$ mL/min, the excess 20 mL/min must be attributed to active secretion.

The blood transits the proximal tubule very rapidly (approximately 30 seconds), leaving insufficient time for complete secretion. The concentration exiting the tubule approximates the unbound concentration. Accordingly:

\[CL_S = \frac{\text{Rate of secretion}}{f_u \cdot C}\]

Both filtration and secretion clearances are influenced by plasma protein binding. The effect of protein binding on renal clearance is therefore more pronounced than it might initially appear.

6.4 6.4 Tubular Reabsorption

Reabsorption is inferred when the observed renal clearance is less than the filtration clearance:

\[CL_R < f_u \cdot GFR \implies \text{reabsorption is occurring}\]

In this case, drug filtered at the glomerulus is being recaptured into the bloodstream from the tubular lumen. This effectively reduces net renal elimination. Although reabsorption occurs for many drugs, filtration and secretion remain the dominant mechanisms in most cases.

6.5 6.5 Measurement of Renal Elimination

Quantitative assessment of renal clearance requires collection of timed urine samples during pharmacokinetic studies. The amount of drug excreted over a defined interval, combined with urine volume, yields the rate of excretion. These measurements will be explored in the context of non-compartmental analysis (NCA).

7 7. Empirical vs. Mechanistic Models: When Each Is Appropriate

The mechanistic framework described above (WellStar model, hepatic and renal clearance equations) underpins drug characterization at the DMPK (drug metabolism and pharmacokinetics) stage, typically in preclinical development.

In clinical pharmacokinetics, empirical models — most commonly first-order elimination — are a good approximation as long as the system behaves linearly. Mechanistic models become necessary when:

Non-linearities are observed (e.g., saturable metabolism, concentration-dependent protein binding).
Drug-drug interactions are being predicted mechanistically.
Inclusion/exclusion criteria for clinical trials need to be designed with pharmacokinetic rationale (e.g., excluding patients whose co-medications alter CYP enzyme activity or protein binding).

For adult-to-pediatric scaling, body weight as a scaling factor is sufficient in the vast majority of cases. PBPK (physiologically based PK) approaches can improve precision in edge cases but require extensive validation.

The fundamental principle throughout is that mechanistic understanding informs good clinical decision-making — particularly for a clinical pharmacologist assessing confounders in trial design, not just fitting models to data.

8 8. Summary of Key Equations

Concept	Equation
Extraction ratio (Well-Stirred)	$E_H = \dfrac{f_{u,B} \cdot CL_{\text{int}}}{Q_H + f_{u,B} \cdot CL_{\text{int}}}$
Hepatic clearance (general)	$CL_H = Q_H \cdot E_H$
High extraction limit	$CL_H \approx Q_H$
Low extraction limit	$CL_H \approx f_{u,B} \cdot CL_{\text{int}}$
Filtration clearance	$CL_F = f_u \cdot GFR$
Total renal clearance	$CL_R = CL_F + CL_S$

--- title: "Hepatic and Renal Clearance: Protein Binding, the Well-Stirred Model, and Renal Elimination Mechanisms" subtitle: "Lecture Notes" format: html: toc: true toc-depth: 3 --- ## 1. Recap: High vs. Low Extraction Ratio Drugs Last session covered the classification of drugs into high and low extraction ratio categories, and the processes that drive that classification. This session dives deeper into two of those processes: the impact of plasma protein binding, and permeability with transporter location. It concludes with renal clearance mechanisms. --- ## 2. Impact of Plasma Protein Binding on Hepatic Clearance ### 2.1 High Extraction Ratio Drugs For a high extraction ratio drug, the dominant process governing elimination is the intrinsic enzymatic capacity of the liver — the liver metabolizes essentially all drug that reaches it. The extraction ratio is defined as: $$E_H = 1 - \frac{C_{B,\text{out}}}{C_{B,\text{in}}}$$ When protein binding changes — whether the fraction unbound increases or decreases — both $C_{B,\text{in}}$ and $C_{B,\text{out}}$ change proportionally. For example, if the ratio was originally $4/4$, it becomes $2/2$ after increased binding; the extraction ratio remains unchanged. Because elimination by the liver is so dominant in high extraction ratio drugs, whatever drug is unbound and enters the hepatocyte is immediately metabolized — assuming no permeability barrier. Therefore: > **For high extraction ratio drugs, changes in plasma protein binding have negligible impact on hepatic clearance.** This is a clinically critical concept. For instance, if a patient is on rifampin (a highly protein-bound drug) and laboratory results indicate a change in albumin levels, the dose need not be adjusted if rifampin is a high extraction ratio drug. ### 2.2 Low Extraction Ratio Drugs For a low extraction ratio drug, the unbound arterial concentration equals the unbound venous concentration: $$C_{A,u} = C_{V,u}$$ At equilibrium — assuming no barriers to penetration — the unbound concentration in the sinusoid equals the unbound intracellular concentration in the hepatocyte: $$C_u = C_{u,H}$$ The rate of elimination can then be written as: $$\text{Rate of elimination} = CL_{\text{int}} \cdot C_{u,H} = CL_{\text{int}} \cdot C_u = CL_{\text{int}} \cdot f_u \cdot C$$ Since hepatic clearance is defined as the rate of elimination divided by concentration: $$CL_H = \frac{\text{Rate of elimination}}{C} = CL_{\text{int}} \cdot f_u$$ Therefore, for a low extraction ratio drug: > **Hepatic clearance is directly proportional to the fraction unbound ($f_u$) and intrinsic clearance ($CL_{\text{int}}$). If $f_u$ increases, $CL_H$ increases proportionally.** This is a fundamental concept. The reason the drug is classified as low extraction is precisely because the enzyme's inherent capacity to metabolize it is low; therefore, the hepatic clearance becomes dependent on plasma protein binding. --- ## 3. The Well-Stirred Model ### 3.1 Fundamental Assumptions The Well-Stirred model (also called the Rowland-Benet model) rests on two core assumptions: 1. The unbound drug concentration is **rapidly equilibrating and uniformly distributed** across the entire organ — including the sinusoids, interstitial spaces, and intracellular hepatocytes. 2. The system is at **steady state**. ### 3.2 Derivation Starting from a mass balance on the liver: $$V_H \frac{dC_H}{dt} = Q_H \cdot C_{B,\text{in}} - Q_H \cdot C_{B,\text{out}} - CL_{\text{int}} \cdot C_{u,\text{cell}}$$ The unbound intracellular concentration is: $$C_{u,\text{cell}} = f_{u,B} \cdot C_{B,\text{out}}$$ Substituting and applying the steady-state condition ($dC_H/dt = 0$): $$Q_H \cdot C_{B,\text{in}} = C_{B,\text{out}} \left(Q_H + f_{u,B} \cdot CL_{\text{int}}\right)$$ Rearranging: $$\frac{C_{B,\text{out}}}{C_{B,\text{in}}} = \frac{Q_H}{Q_H + f_{u,B} \cdot CL_{\text{int}}}$$ Since $E_H = 1 - C_{B,\text{out}}/C_{B,\text{in}}$: $$\boxed{E_H = \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H + f_{u,B} \cdot CL_{\text{int}}}}$$ This is the central equation of the Well-Stirred model. It unifies three determinants of extraction ratio: **fraction unbound**, **intrinsic clearance**, and **hepatic blood flow**. ### 3.3 Limiting Cases **High Extraction Ratio ($E_H \to 1$):** When $f_{u,B} \cdot CL_{\text{int}} \gg Q_H$, the $Q_H$ term in the denominator is negligible: $$E_H \approx \frac{f_{u,B} \cdot CL_{\text{int}}}{f_{u,B} \cdot CL_{\text{int}}} = 1$$ Since $CL_H = Q_H \cdot E_H$: $$CL_H \approx Q_H$$ **Hepatic clearance for high extraction ratio drugs is flow-limited — it depends only on blood flow.** **Low Extraction Ratio ($E_H \ll 1$, typically $< 0.3$):** When $Q_H \gg f_{u,B} \cdot CL_{\text{int}}$: $$E_H \approx \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H}$$ Then: $$CL_H = Q_H \cdot E_H \approx Q_H \cdot \frac{f_{u,B} \cdot CL_{\text{int}}}{Q_H} = f_{u,B} \cdot CL_{\text{int}}$$ **Hepatic clearance for low extraction ratio drugs depends only on $f_{u,B}$ and $CL_{\text{int}}$ — not on blood flow.** Note the important distinction: the extraction ratio itself still depends on all three parameters ($f_{u,B}$, $CL_{\text{int}}$, $Q_H$), but the clearance collapses to only two of them for low extraction drugs. ### 3.4 Extension: Permeability-Surface Area Model At the cellular level, permeability of the hepatocyte membrane is also relevant. Incorporating the permeability-surface area product ($PS_{\text{in}}$), the clearance can be expressed as: $$CL_H = \frac{Q_H \cdot f_{u,B} \cdot PS_{\text{in}}}{Q_H + f_{u,B} \cdot PS_{\text{in}}}$$ The same limiting-case logic applies. For most practical purposes, the simpler $f_{u,B} \cdot CL_{\text{int}}$ formulation is sufficient. --- ## 4. Permeability and Transporter Location The Well-Stirred model assumes that permeability is not rate-limiting. In practice, if a drug has low lipophilicity or a large molecular weight, passive permeability into the hepatocyte may be insufficient. Active transporters at the sinusoidal membrane can compensate, but these cases must be evaluated experimentally on a molecule-by-molecule basis and cannot be resolved through equations alone. --- ## 5. Enterohepatic Recycling In addition to metabolism, elimination from the hepatocyte can occur via **biliary excretion** (secretion into bile). This pathway is generally relevant only for small molecular weight drugs. The sequence is: 1. Drug in hepatocyte is secreted into bile. 2. Bile is stored in the gallbladder. 3. Upon gallbladder emptying, bile enters the small intestine via the bile duct. 4. Drug in the small intestine may be reabsorbed into systemic circulation. This cycle is called **enterohepatic recycling**. A pharmacokinetic consequence is the appearance of a **double-peak phenomenon** in plasma concentration-time profiles: a primary absorption peak followed by a secondary peak coinciding with gallbladder emptying and reabsorption from the gut. --- ## 6. Renal Clearance ### 6.1 Overview of Mechanisms Drugs appear in urine due to three processes in the nephron: - **Filtration** — passive movement of unbound drug from blood into the glomerular filtrate (proximal tubule). - **Secretion** — active transport of drug from blood into the tubular lumen (proximal tubule). - **Reabsorption** — passive or active movement of drug from the tubular lumen back into blood (proximal and distal tubules). The net rate of renal excretion is: $$\text{Rate of excretion} = (1 - F_R)\left(\text{Rate of filtration} + \text{Rate of secretion}\right)$$ where $F_R$ is the fraction reabsorbed. Dividing by plasma concentration gives: $$CL_R = CL_F + CL_S$$ where $CL_F$ is filtration clearance and $CL_S$ is secretion clearance. ### 6.2 Glomerular Filtration Approximately 20–25% of cardiac output (roughly 1.1 L/min) perfuses the kidneys. Of this, approximately 10% is filtered at the glomerulus: $$\text{GFR} \approx 0.10 \times 1{,}100 \text{ mL/min} = 120 \text{ mL/min (in a 70 kg individual)}$$ This value is the **glomerular filtration rate (GFR)**, a key clinical parameter for assessing renally eliminated drugs. Only unbound drug is filtered. The rate of filtration is: $$\text{Rate of filtration} = GFR \cdot C_u = GFR \cdot f_u \cdot C$$ If filtration is the sole elimination pathway, then the rate of urinary excretion equals the rate of filtration, and: $$CL_R = \frac{\text{Rate of excretion}}{C} = f_u \cdot GFR$$ The extraction ratio for such a drug is inherently low. Since GFR ≈ 120 mL/min and renal blood flow ≈ 1,100 mL/min, the extraction ratio is approximately 0.11 — low regardless of the drug's characteristics. ### 6.3 Tubular Secretion Secretion is an **active process** occurring in the proximal tubule. It is inferred when the observed renal clearance exceeds the filtration clearance: $$CL_R > f_u \cdot GFR \implies \text{secretion is present}$$ **Example:** If $f_u = 0.5$ and $GFR = 120$ mL/min, the filtration clearance is 60 mL/min. If the measured $CL_R = 80$ mL/min, the excess 20 mL/min must be attributed to active secretion. The blood transits the proximal tubule very rapidly (approximately 30 seconds), leaving insufficient time for complete secretion. The concentration exiting the tubule approximates the unbound concentration. Accordingly: $$CL_S = \frac{\text{Rate of secretion}}{f_u \cdot C}$$ Both filtration and secretion clearances are influenced by plasma protein binding. The effect of protein binding on renal clearance is therefore more pronounced than it might initially appear. ### 6.4 Tubular Reabsorption Reabsorption is inferred when the observed renal clearance is **less than** the filtration clearance: $$CL_R < f_u \cdot GFR \implies \text{reabsorption is occurring}$$ In this case, drug filtered at the glomerulus is being recaptured into the bloodstream from the tubular lumen. This effectively reduces net renal elimination. Although reabsorption occurs for many drugs, filtration and secretion remain the dominant mechanisms in most cases. ### 6.5 Measurement of Renal Elimination Quantitative assessment of renal clearance requires collection of timed urine samples during pharmacokinetic studies. The amount of drug excreted over a defined interval, combined with urine volume, yields the rate of excretion. These measurements will be explored in the context of non-compartmental analysis (NCA). --- ## 7. Empirical vs. Mechanistic Models: When Each Is Appropriate The mechanistic framework described above (WellStar model, hepatic and renal clearance equations) underpins drug characterization at the DMPK (drug metabolism and pharmacokinetics) stage, typically in preclinical development. In clinical pharmacokinetics, empirical models — most commonly first-order elimination — are a good approximation as long as the system behaves linearly. Mechanistic models become necessary when: - **Non-linearities** are observed (e.g., saturable metabolism, concentration-dependent protein binding). - **Drug-drug interactions** are being predicted mechanistically. - **Inclusion/exclusion criteria** for clinical trials need to be designed with pharmacokinetic rationale (e.g., excluding patients whose co-medications alter CYP enzyme activity or protein binding). For **adult-to-pediatric scaling**, body weight as a scaling factor is sufficient in the vast majority of cases. PBPK (physiologically based PK) approaches can improve precision in edge cases but require extensive validation. The fundamental principle throughout is that mechanistic understanding informs good clinical decision-making — particularly for a clinical pharmacologist assessing confounders in trial design, not just fitting models to data. --- ## 8. Summary of Key Equations | Concept | Equation | |---|---| | Extraction ratio (Well-Stirred) | $E_H = \dfrac{f_{u,B} \cdot CL_{\text{int}}}{Q_H + f_{u,B} \cdot CL_{\text{int}}}$ | | Hepatic clearance (general) | $CL_H = Q_H \cdot E_H$ | | High extraction limit | $CL_H \approx Q_H$ | | Low extraction limit | $CL_H \approx f_{u,B} \cdot CL_{\text{int}}$ | | Filtration clearance | $CL_F = f_u \cdot GFR$ | | Total renal clearance | $CL_R = CL_F + CL_S$ |